A biosimilar co-developed by generics giant Mylan and Indian biopharmaceutical company Biocon (NSE: BIOCON) is as effective in treating HER2 metastatic breast cancer as Herceptin (trastuzumab), according to the results of a Phase III clinical trial.
The global HERITAGE study, which was conducted at 95 sites across Asia, Latin America, Africa and Europe, confirmed efficacy, safety and immunogenicity of the proposed biosimilar MYL-14010 in comparison to Genentech's branded trastuzumab, Herceptin.
The data was presented on the first day of ASCO 2016, which is taking place in Chicago this week (June 3-7).
